Ro Khanna Backs Bill for Trump’s Drug Price Cuts

---

Full Story

President Trump has signed an executive order to slash prescription drug prices by 30% to 80%, using a “Most Favored Nation” policy to match U.S. costs with the lowest prices in other developed nations. Democratic Representative Ro Khanna expressed support, announcing plans to introduce the order as a bipartisan bill in Congress. The proposed legislation aims to make the price reductions permanent, potentially in collaboration with Senator Bernie Sanders. This move addresses long-standing concerns about high drug costs in the U.S.

The executive order targets the pharmaceutical industry’s pricing practices. It seeks to align U.S. drug costs with those in countries like Canada or European nations.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 30% | Right 24% | Center 36% | Unrated 9%

The Context

The “Most Favored Nation” policy would tie U.S. prices to international benchmarks. This could lower costs for millions of Americans reliant on prescription medications.

Ro Khanna’s push for a bipartisan bill reflects growing congressional interest in drug affordability. He aims to codify the policy to prevent future reversals.

Collaboration with Senator Sanders suggests a focus on progressive health care priorities. Sanders has long advocated for systemic reforms to reduce drug prices.

The U.S. spends over $400 billion annually on prescription drugs, per government data. High costs have fueled public demand for federal action over decades.

Some support the policy, arguing it promotes fairness and eases financial burdens. Others worry it could stifle innovation in the pharmaceutical sector.

Drug pricing reforms have historically faced resistance from industry stakeholders. Past efforts, like the Affordable Care Act, only partially addressed costs.